Mepron and Neulasta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mepron (atovaquone) and Neulasta (pegfilgrastim). Common drug interactions include leukocytosis among females and febrile neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Mepron and Neulasta. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Mepron?

Mepron has active ingredients of atovaquone. It is often used in babesiosis. eHealthMe is studying from 2,091 Mepron users. Check the latest studies of Mepron.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

On Jul, 26, 2026

20 people who take Mepron and Neulasta together, and have interactions are studied.

What are the common drug interactions of Mepron and Neulasta, by gender? *:

female:

Leukocytosis (increased white blood cells)
Anaemia (lack of blood)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Diarrhoea
Diplopia (double vision)
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Febrile neutropenia (fever with reduced white blood cells)
Hypokalaemia (low potassium)
Melaena (the passage of black, tarry stools)
Myasthenic syndrome (a group of conditions characterized by muscle weakness (myasthenia) that worsens with physical exertion)

male:

Febrile neutropenia (fever with reduced white blood cells)
Bacteraemia (presence of bacteria in the blood)
Escherichia urinary tract infection (urinary tract infection by escherichia coli)
Prostatic abscess (a closed pocket containing pus within the prostate)
Urethral fistula
Lymphocyte count decreased
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Platelet count decreased
White blood cell count decreased
Lung infection

What are the common drug interactions of Mepron and Neulasta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Multiple myeloma (cancer of the plasma cells)
Sepsis (a severe blood infection that can lead to organ failure and death)
Death

50-59:

Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
Leukocytosis (increased white blood cells)

60+:

Febrile neutropenia (fever with reduced white blood cells)
Bacteraemia (presence of bacteria in the blood)
Diplopia (double vision)
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Hypokalaemia (low potassium)
Leukocytosis (increased white blood cells)
Melaena (the passage of black, tarry stools)
Myasthenic syndrome (a group of conditions characterized by muscle weakness (myasthenia) that worsens with physical exertion)
Procedural pain
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

Stress And Anxiety: 13 people, 65.00%
Nausea (feeling of having an urge to vomit): 9 people, 45.00%
Nausea And Vomiting: 8 people, 40.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 8 people, 40.00%
Constipation: 7 people, 35.00%
Diarrhea: 5 people, 25.00%
Akathisia (a movement disorder characterized by a feeling of inner restlessness): 5 people, 25.00%
Flatulence (flatus expelled through the anus): 5 people, 25.00%
High Blood Pressure: 4 people, 20.00%
Hypokalemia (low potassium): 4 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mepron and Neulasta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously